Evaluation of Serum Fibrinogen, Plasminogen, α2-Anti-Plasmin, and Plasminogen Activator Inhibitor Levels (PAI) and Their Correlation with Presence of Retinopathy in Patients with Type 1 DM
Background. Diabetic retinopathy (DR) is the leading cause of blindness in the world. Retinopathy can still progress despite optimal metabolic control. The aim of the study was to determine whether different degrees of DR (proliferative or nonproliferative) were associated with abnormally modulated...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2014-01-01
|
| Series: | Journal of Diabetes Research |
| Online Access: | http://dx.doi.org/10.1155/2014/317292 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850232461744668672 |
|---|---|
| author | Sefika Burcak Polat Nagihan Ugurlu Fatma Yulek Huseyin Simavli Reyhan Ersoy Bekir Cakir Ozcan Erel |
| author_facet | Sefika Burcak Polat Nagihan Ugurlu Fatma Yulek Huseyin Simavli Reyhan Ersoy Bekir Cakir Ozcan Erel |
| author_sort | Sefika Burcak Polat |
| collection | DOAJ |
| description | Background. Diabetic retinopathy (DR) is the leading cause of blindness in the world. Retinopathy can still progress despite optimal metabolic control. The aim of the study was to determine whether different degrees of DR (proliferative or nonproliferative) were associated with abnormally modulated hemostatic parameters in patients with T1DM. Method. 52 T1DM patients and 40 healthy controls were enrolled in the study. Patients were subdivided into three categories. Group I was defined as those without retinopathy, group II with NPRP, and group III with PRP. We compared these subgroups with each other and the control group (Group IV) according to the serum fibrinogen, plasminogen, alpha2-anti-plasmin (α2-anti-plasmin), and PAI. Results. We detected that PAI-1, serum fibrinogen, and plasminogen levels were similar between the diabetic and control groups (P=0.209, P=0.224, and P=0.244, resp.), whereas α2-anti-plasmin was higher in Groups I, II, and III compared to the control group (P<0.01, P<0.05, and P<0.001, resp.). There was a positive correlation between serum α2-anti-plasmin and HbA1c levels (r=0,268, P=0.031). Conclusion. To our knowledge there is scarce data in the literature about α2-anti-plasmin levels in type 1 diabetes. A positive correlation between α2-anti-plasmin with HbA1c suggests that fibrinolytic markers may improve with disease regulation and better glycemic control. |
| format | Article |
| id | doaj-art-0a8b9caa5b9e4bd69fced4a11721dc05 |
| institution | OA Journals |
| issn | 2314-6745 2314-6753 |
| language | English |
| publishDate | 2014-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Journal of Diabetes Research |
| spelling | doaj-art-0a8b9caa5b9e4bd69fced4a11721dc052025-08-20T02:03:12ZengWileyJournal of Diabetes Research2314-67452314-67532014-01-01201410.1155/2014/317292317292Evaluation of Serum Fibrinogen, Plasminogen, α2-Anti-Plasmin, and Plasminogen Activator Inhibitor Levels (PAI) and Their Correlation with Presence of Retinopathy in Patients with Type 1 DMSefika Burcak Polat0Nagihan Ugurlu1Fatma Yulek2Huseyin Simavli3Reyhan Ersoy4Bekir Cakir5Ozcan Erel6Endocrinology and Metabolism Department, Ataturk Training and Research Hospital, Yildirim Beyazit University, 6800 Ankara, TurkeyOphthalmology Department, Ataturk Training and Research Hospital, Yildirim Beyazit University, Ankara, TurkeyOphthalmology Department, Ataturk Training and Research Hospital, Yildirim Beyazit University, Ankara, TurkeyOphtalmology Department, Izzet Baysal Government Hospital, Bolu, TurkeyEndocrinology and Metabolism Department, Ataturk Training and Research Hospital, Yildirim Beyazit University, 6800 Ankara, TurkeyEndocrinology and Metabolism Department, Ataturk Training and Research Hospital, Yildirim Beyazit University, 6800 Ankara, TurkeyDepartment of Biochemistry, Ataturk Training and Research Hospital, Yildirim Beyazit University, Ankara, TurkeyBackground. Diabetic retinopathy (DR) is the leading cause of blindness in the world. Retinopathy can still progress despite optimal metabolic control. The aim of the study was to determine whether different degrees of DR (proliferative or nonproliferative) were associated with abnormally modulated hemostatic parameters in patients with T1DM. Method. 52 T1DM patients and 40 healthy controls were enrolled in the study. Patients were subdivided into three categories. Group I was defined as those without retinopathy, group II with NPRP, and group III with PRP. We compared these subgroups with each other and the control group (Group IV) according to the serum fibrinogen, plasminogen, alpha2-anti-plasmin (α2-anti-plasmin), and PAI. Results. We detected that PAI-1, serum fibrinogen, and plasminogen levels were similar between the diabetic and control groups (P=0.209, P=0.224, and P=0.244, resp.), whereas α2-anti-plasmin was higher in Groups I, II, and III compared to the control group (P<0.01, P<0.05, and P<0.001, resp.). There was a positive correlation between serum α2-anti-plasmin and HbA1c levels (r=0,268, P=0.031). Conclusion. To our knowledge there is scarce data in the literature about α2-anti-plasmin levels in type 1 diabetes. A positive correlation between α2-anti-plasmin with HbA1c suggests that fibrinolytic markers may improve with disease regulation and better glycemic control.http://dx.doi.org/10.1155/2014/317292 |
| spellingShingle | Sefika Burcak Polat Nagihan Ugurlu Fatma Yulek Huseyin Simavli Reyhan Ersoy Bekir Cakir Ozcan Erel Evaluation of Serum Fibrinogen, Plasminogen, α2-Anti-Plasmin, and Plasminogen Activator Inhibitor Levels (PAI) and Their Correlation with Presence of Retinopathy in Patients with Type 1 DM Journal of Diabetes Research |
| title | Evaluation of Serum Fibrinogen, Plasminogen, α2-Anti-Plasmin, and Plasminogen Activator Inhibitor Levels (PAI) and Their Correlation with Presence of Retinopathy in Patients with Type 1 DM |
| title_full | Evaluation of Serum Fibrinogen, Plasminogen, α2-Anti-Plasmin, and Plasminogen Activator Inhibitor Levels (PAI) and Their Correlation with Presence of Retinopathy in Patients with Type 1 DM |
| title_fullStr | Evaluation of Serum Fibrinogen, Plasminogen, α2-Anti-Plasmin, and Plasminogen Activator Inhibitor Levels (PAI) and Their Correlation with Presence of Retinopathy in Patients with Type 1 DM |
| title_full_unstemmed | Evaluation of Serum Fibrinogen, Plasminogen, α2-Anti-Plasmin, and Plasminogen Activator Inhibitor Levels (PAI) and Their Correlation with Presence of Retinopathy in Patients with Type 1 DM |
| title_short | Evaluation of Serum Fibrinogen, Plasminogen, α2-Anti-Plasmin, and Plasminogen Activator Inhibitor Levels (PAI) and Their Correlation with Presence of Retinopathy in Patients with Type 1 DM |
| title_sort | evaluation of serum fibrinogen plasminogen α2 anti plasmin and plasminogen activator inhibitor levels pai and their correlation with presence of retinopathy in patients with type 1 dm |
| url | http://dx.doi.org/10.1155/2014/317292 |
| work_keys_str_mv | AT sefikaburcakpolat evaluationofserumfibrinogenplasminogena2antiplasminandplasminogenactivatorinhibitorlevelspaiandtheircorrelationwithpresenceofretinopathyinpatientswithtype1dm AT nagihanugurlu evaluationofserumfibrinogenplasminogena2antiplasminandplasminogenactivatorinhibitorlevelspaiandtheircorrelationwithpresenceofretinopathyinpatientswithtype1dm AT fatmayulek evaluationofserumfibrinogenplasminogena2antiplasminandplasminogenactivatorinhibitorlevelspaiandtheircorrelationwithpresenceofretinopathyinpatientswithtype1dm AT huseyinsimavli evaluationofserumfibrinogenplasminogena2antiplasminandplasminogenactivatorinhibitorlevelspaiandtheircorrelationwithpresenceofretinopathyinpatientswithtype1dm AT reyhanersoy evaluationofserumfibrinogenplasminogena2antiplasminandplasminogenactivatorinhibitorlevelspaiandtheircorrelationwithpresenceofretinopathyinpatientswithtype1dm AT bekircakir evaluationofserumfibrinogenplasminogena2antiplasminandplasminogenactivatorinhibitorlevelspaiandtheircorrelationwithpresenceofretinopathyinpatientswithtype1dm AT ozcanerel evaluationofserumfibrinogenplasminogena2antiplasminandplasminogenactivatorinhibitorlevelspaiandtheircorrelationwithpresenceofretinopathyinpatientswithtype1dm |